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a b s t r a c t
Introduction: Diarrhea is a leading cause of mortality worldwide and rotavirus accounts for many of these
deaths. As of August 2018, 96 countries have introduced rotavirus vaccines into their immunization pro-
grams. Two rotavirus vaccines, Rotarix and RotaTeq, have been WHO-prequalified since 2009, with
Rotarix being the preferred product of most Gavi-supported countries. ROTAVAC and ROTASIIL have
both been prequalified recently.
Materials and methods: We reevaluated the costs and cost-effectiveness of rotavirus vaccination in
Bangladesh, Ghana, and Malawi and compared Rotarix, ROTAVAC, and ROTASIIL in each country.
For consistency with previously published analyses in these countries, we used the same Excel-based
cohort model and much of the same data as the original analyses. We varied the expected price (with
and without Gavi subsidy), wastage, and incremental health system costs associated with each vaccine.
We assumed the same efficacy and waning assumptions following administration of two or three doses
for the respective product.
Results: The discounted cost per DALY averted compared to no vaccination ranged from 0.3 to 1.3 times
GNI per capita for each vaccine. With the Gavi subsidy, the average cost-effectiveness ratios were below
0.3 times GNI per capita in all three countries. Though critical empirical cost data are not yet available,
Rotarix is the least costly and most cost-effective product in the countries examined in this modelling
study. However, small decreases in the incremental health system cost for other products could result in
cost and cost-effectiveness outcomes that match or surpass those of Rotarix.
Conclusion: Countries may wish to consider new rotavirus vaccines entering the market. Countries
should carefully examine multiple product attributes including price and the incremental health system
costs associated with each vaccine. These costs will vary by country and may be a defining factor in deter-
mining the least costly and most cost-effective product for the population.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Diarrhea is a leading cause of childhood mortality worldwide,
causing 9% of all under-5 deaths [1–3]. Rotavirus accounts for
24–37% of these deaths [3], resulting in an estimated 200,000
deaths annually [4]. The World Health Organization (WHO) recom-
mended rotavirus vaccination in all countries’ national immuniza-
tion programs in 2009, and as of August 2018 96 countries have
introduced rotavirus vaccine [5,6]. Gavi, the Vaccine Alliance pro-
vides support for rotavirus vaccination to eligible low- and
middle-income countries (LMICs), and more than 40 countries
have introduced with Gavi support [6,7]. Numerous other
countries have recently been approved for Gavi rotavirus vaccine
https://doi.org/10.1016/j.vaccine.2018.10.068
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support [8]. Recent approvals in countries with large birth cohorts
include Afghanistan, Bangladesh, Democratic Republic of the
Congo, Nigeria, and Pakistan. India has introduced rotavirus vacci-
nation in at least six states and will continue to expand the pro-
gram nationally with domestically manufactured products
(ROTAVAC and ROTASIIL). Together, these six countries account
for more than 30% of the world’s infants [9].
The introduction of rotavirus vaccination in these countries pro-
mises to substantially reduce rotavirus disease burden and deaths
but may pressure current vaccine supplies. Two rotavirus vaccines
have been WHO-prequalified for global use since 2009: Rotarix (a
registered trademark of GlaxoSmithKline Biologicals SA, used
under license by GlaxoSmithKline Inc.) and RotaTeq (a registered
trademark of Merck & Co., Inc.) [10]. However, ROTAVAC (Bharat
Biotech International Limited) and ROTASIIL (Serum Institute of
India) were recently prequalified by WHO [11,12]. WHO-
prequalification ensures a product meets quality, safety and effi-
cacy requirements allowing its purchase by international procure-
ment agencies. This enables more manufacturers to enter the
international market, increasing choice, and lowering supply
pressure.
Product selection is a complex, multifactorial decision, and each
introducing country assesses the advantages and disadvantages of
competing products. In addition to differences in efficacy and
safety among products, decision-makers may consider the poten-
tial costs of introduction and implementation and how this will
affect cost-effectiveness. Such costs include the vaccine costs
(e.g., price of the vaccine, international handling, transportation
costs, and wastage) and costs to the health system (e.g., subna-
tional vaccine distribution, cold chain expansion, and staff training
and labor for service delivery or program management). As many
countries transition away from Gavi financial support and toward
self-financing of vaccines, these economic considerations become
increasingly important.
In this analysis, we reevaluate cost-effectiveness studies previ-
ously conducted in Bangladesh, Ghana, and Malawi [13–15]. Our
objective is to compare the economic impacts of three vaccines
(Rotarix, ROTAVAC, and ROTASIIL) as though they were all
available at the time of the original analyses. Although RotaTeq
was an available product at the time, the previous studies each
examined Rotarix as a country-preferred product. As a result,
we did not include RotaTeq in this analysis. Using previously pub-
lished national cost-effectiveness studies allows us to leverage
model inputs that have already been gathered, reviewed, and
accepted by participating national stakeholders. Our aim is not to
advocate for any particular product, but to explore the sensitivity
of costs and cost-effectiveness of available products to a range of
transparent assumptions within and across three countries at dif-
ferent levels of Gavi support.
2. Materials and methods
2.1. Model inputs and assumptions
The authors recently undertook impact and cost-effectiveness
analyses of rotavirus vaccination in Bangladesh, Ghana, and
Malawi [13–15]. Each analysis used the TRIVAC model, a static
cohort model developed at the London School of Hygiene and Trop-
ical Medicine with support from the Pan American Health Organi-
zation’s ProVac Initiative. TRIVAC models consecutive birth cohorts
to generate impact and cost-effectiveness estimates of rotavirus
and other vaccines. Model inputs include demographic projections,
disease incidence and mortality rates, vaccine efficacy (allowing
for possible waning), vaccine coverage, timeliness of uptake, vac-
cine program costs, health service utilization rates, and treatment
and households costs [16]. Analyses were adapted to country con-
text and undertaken at different time points relative to vaccine
introduction, which had implications for the use of local data in
the analysis. For example, the Bangladesh analysis was undertaken
prior to vaccine introduction and used projections for vaccine
effectiveness. Conversely, the Malawi analysis was undertaken
after vaccine introduction and local effectiveness data were avail-
able to inform the analysis. All examined Rotarix as a country-
preferred product.
The current analysis follows the prior studies as closely as possi-
ble anduses the sameassumptions anddatawherever possible, only
varying inputs to reflect core characteristics of the new products
that differ from Rotarix. We do not attempt to harmonize inputs
to make the results comparable across countries. Rather, we main-
tain consistency with the previously published studies to allow
comparisons between vaccine products in the individual countries.
Someparameters (e.g. severityof diseaseor treatment seeking rates)
may differ across countries. We do not explore these cross country
differences here but the rationale for those input parameters can
be found in the original papers. Tables 1 and S1 in supplementary
materials highlight the characteristics and data inputs that remain
consistent between the initial studies and this analysis.
In each analysis, the model tracks the designated birth cohorts
over the first five years of life. Individuals may or may not get dis-
ease. If they get rotavirus disease, it can be severe or non-severe,
and treatment may or may not be received and can occur at infor-
mal (Bangladesh only), outpatient, or inpatient facilities. Non-
severe disease results in recovery, whereas severe disease may
result in recovery or death.
2.2. Alternative data inputs to reflect new vaccine products
Data inputs altered to account for alternative vaccine products
include the number of doses, coverage of the third dose (if applica-
ble), vaccine wastage, efficacy, incremental health system cost, and
vaccine price (Table 2).
Rotarix has a two-dose schedule, while ROTAVAC and ROTA-
SIIL have three-dose schedules [11]. We incorporate the third
dose for ROTAVAC and ROTASIIL with coverage at DTP3 levels.
Rotarix is modelled as a single-dose presentation with 5% wastage
[11]. ROTAVAC is modelled as a five-dose presentation, resulting
in smaller storage volume but a higher wastage rate of 25% [17,18].
Some sources suggest wastage as high as 50% for this presentation,
but we utilized a lower wastage to reflect the 5-dose presentation
and expectations that wastage may fall over time [11]. ROTASIIL
is modelled as a two-dose presentation and a larger volume than
Rotarix and ROTAVAC. When examining ROTASIIL, we maintain
the 5% wastage rates utilized in our prior country analyses of
Rotarix [11]. While vaccine efficacy may differ by product, we
do not believe there is sufficient evidence to differentiate by pro-
duct in these countries, so we assume values consistent with the
prior analyses [19]. Incremental health system cost per dose
depends on various factors such as vaccine presentation, vaccine
volume, cold chain and transport requirements, delivery process,
and training needs, but quantifying these components precisely
is challenging without extensive in-country data collection. As data
collection is beyond the scope of this analysis, we conducted a
threshold analysis to examine how changes in incremental health
system costs influence the results.
When comparing alternative vaccine products, we consider two
alternative price scenarios in each country (Fig. S1 in supplemen-
tary materials). The first scenario assumes the country pays the
Gavi price, which would remain constant for all years in the anal-
ysis. For this scenario we used a Gavi price-per-dose of US$2.02,
$2.00, and $1.00 for Rotarix, ROTASIIL and ROTAVAC,
respectively [11,20]. The second scenario assumes that each coun-
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try would support a co-financing share per dose based on Gavi’s
co-financing policy and each country’s co-financing status [8,21].
Malawi is an Initial Self-Financing country supporting a minimum
co-financing of $0.20 per dose of vaccine. Per Gavi’s policy, a coun-
try in this group selecting a three-dose rotavirus vaccine pays only
two-thirds of the per-dose price, so a three-dose rotavirus vaccine
represents the same co-financing commitment as a two-dose vac-
cine [22]. Malawi is assumed to remain in this phase for the period
of analysis. Bangladesh is a Preparatory Transition country, mean-
ing that its co-financing share would increase by 15% per year. We
assume Bangladesh stays in this phase over the duration of the
analysis. The average cost per dose for Bangladesh is therefore
$0.14, $0.29, and $0.29 for ROTAVAC, ROTASIIL, and Rotarix,
respectively. Ghana entered the Accelerated Transition phase in
2017; assuming Ghana remains in this phase, the co-financing
share increases linearly until full price is reached in 20221. The
average co-financing per dose over the period of analysis for Ghana
is $0.78, $1.55, and $1.57 for ROTAVAC, ROTASIIL, and Rotarix,
respectively.
In addition to examining a variety of scenarios, we also under-
took a threshold analysis to examine the robustness of our results
by varying the incremental health system cost per dose of the
alternative products. Specifically, we reduced the incremental
health system cost per dose for more costly products until the total
cost of delivery and cost-effectiveness ratio were equivalent to the
values obtained for the lowest cost product. The incremental
Table 1
Key model inputs consistent with prior analyses.
Parameter Bangladesh Ghana Malawi Source/s
Annual rotavirus events pre-vaccination
Non-severe cases/100,000 aged <5 years 7300 9290 9201 Bangladesh: assumption based on [27,28,29]
Ghana: assumption based on [30,31]
Malawi: assumption based on [16,32]
Severe cases/100,000 aged <5 years 2700 710 799
Rotavirus gastroenteritis mortality/100,000 aged <5 years 12.42 46.15 33.48 Bangladesh: assumption based on [4,33]
Ghana: calibrated to align with [4]
Malawi: assumption based on [34,35,36]
Non-severe outpatient visits/100,000 aged <5 years 3431 4181 5797 Bangladesh: assumption based on [37,38]
Ghana: [39]
Malawi: [15]
Severe outpatient visits/100,000 aged <5 years 1269 320 503 Bangladesh: assumption based on [37,38]
Ghana: [39]
Malawi: [15]
Hospitalizations/100,000 aged <5 years 1107 568 503 Bangladesh: assumption based on [26,27]
Ghana: assumption based on local expert opinion
Malawi: [15]
Disability weight for DALY calculations
Rotavirus (non-severe) cases 0.188 0.188 0.202 Bangladesh and Ghana [40]
Malawi [41]
Rotavirus (severe) cases 0.247 0.247 0.281 Bangladesh and Ghana [32]
Malawi [33]
Mean duration of illness (in days)
Rotavirus (non-severe) cases 6 3 6 Assumption
Rotavirus (severe) cases 6 5 6 Assumption
Cumulative age distribution of disease
<3 months: 0.5% 7.1% 6.6% Bangladesh: [42]
Ghana: [43]
Malawi: [44]
<6 months: 6.6% 24.2% 26%
<12 months: 51.1% 70% 77.7%
<24 months: 97.1% 98.6% 99.5%
<60 months: 100% 100% 100%
Health service costs
Government cost per visit
Non-severe rotavirus cases
Facility (outpatient) $1.88 $1.61–$6.15* $7.02–$8.02* Bangladesh: [45]
Ghana: [46]
Malawi: [15]
Severe rotavirus cases
Facility (inpatient) $11.41 $22.71–$48.57* $8.02–$46.34* Bangladesh: [47]
Ghana: [38]
Malawi: [15]
Household cost per visit
Non-severe rotavirus cases
Informal $1.17 – – Bangladesh: [37]
Facility (outpatient) $1.39 $0.72–$2.75* $0.09–$5.80* Bangladesh: [37]
Ghana: calculated using [48]
Malawi: [15]
Severe rotavirus cases
Informal $1.17 – – Bangladesh: [37]
Facility (inpatient) $51.21 $10.17–$21.74* $0.11–$13.75* Bangladesh: [39]
Ghana: calculated using [37]
Malawi: [15]
* Ranges reflect costs associated with care at different facility types.
1 In 2018, Ghana re-entered the Gavi Preparatory Transition phase, although to
ensure consistency with the previous cost-effectiveness study, we do not reflect this
change in this analysis.
7474 C. Pecenka et al. / Vaccine 36 (2018) 7472–7478
health system cost per dose includes all non-vaccine-related costs
such as vaccine distribution, cold chain expansion, staff training,
and labor for service delivery or program management.
3. Results
The principal results of this study are health impact, cost-
effectiveness, and cost comparisons among three rotavirus vaccine
products for three countries at different phases of Gavi support.
Health benefits provided by rotavirus vaccination remain
unchanged from prior studies and are similar across vaccines in
the same country as we assume comparable protection conferred
by different products. Detailed impact results are available in
Table 3.
The discounted cost per DALY averted compared to no vaccina-
tion ranged from 0.3 to 1.3 times GNI per capita for all vaccines.
With the Gavi subsidy, the average cost-effectiveness ratios were
below 0.3 times GNI per capita in all three countries. Cost and
cost-effectiveness results for the three countries and the three vac-
cines are displayed in Table 4. Within an individual country, all
vaccines had generally similar cost-effectiveness ratios compared
to no vaccination. However, in most cases the two-dose vaccine
Rotarix was the most cost-effective followed by ROTAVAC and
then ROTASIIL.
Co-financing, which varies by Gavi status, is critical to under-
standing the costs of the vaccination programs. As such, we exam-
ine these costs by country at different stages of Gavi support. Note
that overall costs are not comparable across countries due to dif-
fering population sizes, birth cohorts, and other factors.
3.1. Initial self-financing
In Malawi, the total cost of the vaccine program with a Gavi
subsidy ranged from $10.2 million using Rotarix to $14.5 million
using ROTAVAC, and from $42.1 million using Rotarix to $62.6
million using ROTASIIL without a subsidy. The total cost of the
program to the country, accounting for the Gavi subsidy, was low-
est using Rotarix followed by ROTASIIL and then ROTAVAC. The
total cost of the program without accounting for the subsidy, thus
representing the joint country and Gavi cost, was again lowest
using Rotarix then followed by ROTAVAC and ROTASIIL. Note
the ordering by vaccine is different from the country and Gavi per-
spectives. If we only consider the cost of the vaccine from the
country perspective, Rotarix and ROTASIIL were equally costly
and the cost of ROTAVAC was higher. ROTAVAC, however, was
the least costly vaccine when considering the country and Gavi
vaccine cost together. Rotarix vaccine costs were only slightly
higher followed by higher vaccine costs for ROTASIIL. Incremental
health system costs borne by countries include everything but the
vaccine costs and procurement charges (e.g., international shipping
and handling, wastage). Two-dose regimens were therefore two-
thirds the cost of three-dose regimen.
3.2. Preparatory transition
In Bangladesh, the total cost of the vaccination program with a
Gavi subsidy ranged from approximately $42million using Rotarix
to nearly $62millionusingROTASIIL, and fromalmost $136million
usingRotarix to approximately $200millionusingROTASIILwith-
out a subsidy. The total cost of the program, accounting for the Gavi
subsidy and thus representing the cost to the country, was lowest
usingRotarix followedbyROTAVAC and thenROTASIIL. The total
cost of the program without accounting for the Gavi subsidy fol-
lowed the same order. Considering only the cost of the vaccine from
the country perspective, ROTAVAC was the least expensive fol-
lowed closely by Rotarix and then ROTASIIL. The same ordering
held when considering the country and Gavi vaccine cost together.
Incremental health system costs for the two-dose coursewere again
two-thirds of the three-dose course.
3.3. Accelerated transition
In Ghana, the total cost of the vaccination program with a Gavi
subsidy ranged from approximately $68 million using Rotarix to
Table 3
Key model outputs by country.
Bangladesh Ghana Malawi
Baseline year 2017 2012 2013
Vaccinated cohorts 10 20 20
Baseline rotavirus admissions (annual) 160,000 22,000 15,000
Baseline rotavirus cases (annual) 1.5 million 390,000 290,000
Model output with vaccination over period of analysis, benefits discounted*
Deaths averted per 100,000 129 1047 662
DALYs averted per 100,000 4230 29,872 20,918
Cases averted per 100,000 126,271 261,574 157,460
Inpatient visits averted per 100,000 14,707 14,857 11,996
Outpatient visits averted per 100,000 39,862 109,108 84,384
Informal ‘‘visits” averted per 100,000 56,656 n/a n/a
* For ease of reading, figures have been adjusted by 100,000 live births, absolute
figures available in Table S3 in supplementary materials.
Table 2
Model inputs that vary by vaccine selection.
Bangladesh
(Rotarix; ROTAVAC;
ROTASIIL)
Ghana
(Rotarix; ROTAVAC;
ROTASIIL)
Malawi
(Rotarix; ROTAVAC;
ROTASIIL)
Sources
Doses 2; 3; 3 2; 3; 3 2; 3; 3 [11]
Vaccine coverage in year of introduction
Dose 1 97% 94% 90% Bangladesh: [49]
Ghana: [50]
Malawi: [36]
Dose 2 96% 92% 87%
Dose 3 94% 90% 84%
Vaccine wastage 5%; 25%; 5% 5%; 25%; 5% 5%; 25%; 5% [11,18]
Vaccine efficacy, severe disease*
Full course 48% 65% 64% Bangladesh: [51]
Ghana: [52]
Malawi: [36]
Waning (relative decrease per year) 36.0% 54.7% 47.5%
Incremental health system cost per
dose
$0.54 $1.30 $0.42 Bangladesh: derived from
[53]
Ghana: [54]
Malawi: derived from [55]
* Effectiveness data was used in Malawi though we use the term efficacy for consistency across countries.
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$100.5 million using ROTASIIL and from nearly $90 million using
Rotarix to approximately $130 million using ROTASIIL without a
subsidy. The total cost of the program to the country, accounting
for the Gavi subsidy, was lowest using Rotarix followed by ROTA-
VAC and then ROTASIIL. The total cost of the program, without
accounting for the Gavi subsidy, followed the same order. Consid-
ering the cost of the vaccine from the country perspective, ROTA-
VAC was the least expensive followed closely by Rotarix and
then ROTASIIL. The same ordering held when considering the
country and Gavi vaccine costs together. Incremental health sys-
tem costs for the two-dose course were again two-thirds of the
three-dose course.
Fig. 1 shows the cost per DALY averted and total cost of vac-
cination program for each country and each vaccine, with or
without Gavi subsidy. Rotarix is the least costly and most cost
effective product in all scenarios. In the left panel showing Ban-
gladesh, the location of the vaccines is driven more by the inclu-
sion of a Gavi subsidy or not rather than differences between
vaccines. This reflects Bangladesh’s large population and an
intermediate level of co-financing support from Gavi. As Gavi
support declines, the vaccine program will become more expen-
sive and less cost effective. Ghana already pays a larger share of
its vaccine costs so variation in the central panel shows a smaller
change in cost and cost effectiveness for any of the vaccines as
Gavi support declines. Finally, Malawi benefits from more Gavi
support and has a smaller population so the cost of the vaccina-
tion program does not reach the same levels as Gavi support
declines. However, there is variation in the cost effectiveness of
the vaccine program.
3.4. Threshold analysis
While Rotarix resulted in the least expensive vaccination pro-
gram across the examined countries, we undertook a threshold
analysis to understand the consistency of this finding by varying
the incremental health system cost per dose of the alternative
products. Table 5 illustrates the per-dose incremental health sys-
tem cost as well as the percentage and absolute reduction in incre-
mental health system costs at which costs and cost-effectiveness
are equivalent to Rotarix. Any incremental health system cost
value below the value in the table would result in a cost and
cost-effectiveness advantage for the associated vaccine product.
For example in Bangladesh with a Gavi subsidy, the incremental
health system cost per dose of ROTAVAC would have to be
$0.16 (or 30%) lower than those of Rotarix for the costs and
cost-effectiveness of ROTAVAC to be equal to Rotarix. The decli-
nes in incremental health system costs varies by product and sce-
nario but ranges from declines of 14% to more than 100% in some
instances.
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Fig. 1. Cost per DALY averted and vaccination program cost.
Table 4
Cost and cost-effectiveness by country and vaccine product.
Bangladesh Ghana Malawi
Rotarix ROTAVAC ROTASIIL Rotarix ROTAVAC ROTASIIL Rotarix ROTAVAC ROTASIIL
Model output with vaccination over period of analysis, benefits and costs discounted (millions)
Health costs averted
(government/societal)
$7.0/$33.7 $6.3/$9.1 $8.0/$9.2
Total cost of vaccination
program with/without
Gavi subsidy
$41.6/$135.7 $53.5/$141.4 $61.7/$200.5 $67.9/$88.9 $81.5/$101.0 $100.5/$131.3 $10.2/$42.1 $14.5/$43.3 $13.5/$62.6
Cost of vaccine with/without
Gavi subsidy
$15.1/$109.3 $14.1/$102.1 $22.3/$161.1 $35.2/$56.2 $32.8/$52.4 $51.9/$82.7 $3.5/$35.5 $4.5/$33.3 $3.5/$52.6
Incremental health system cost $26.4 $39.4 $39.4 $32.7 $48.6 $48.6 $6.7 $10.0 $10.0
Model output with vaccination over period of analysis, benefits and costs discounted
Cost/DALY averted
with/without Gavi subsidy
$61/$789 $153/$833 $216/$1290 $230/$312 $283/$360 $358/$479 $7/$241 $38/$250 $32/$392
Cost/DALY averted as
a share of GNI per capita
with/without Gavi subsidy
0.05/0.59 0.12/0.63 0.16/0.97 0.16/0.23 0.21/0.26 0.26/0.35 0.02/0.75 0.12/0.78 0.10/1.23
GNI per capita,
Atlas method (2016)*
$1330 $1380 $320
* https://data.worldbank.org/indicator/NY.GNP.PCAP.CD.
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4. Discussion
Rotavirus vaccination substantially reduces rotavirus illness,
hospitalization, and death in each of the examined countries. In
addition, each of the vaccine products is projected to be highly
cost-effective relative to no vaccination from the country perspec-
tive, even with conservative cost-effectiveness thresholds [23,24].
We did not undertake a head-to-head cost-effectiveness compar-
ison of the vaccines, which would require more detailed vaccine
performance and cost of delivery data and would not be appropri-
ate for this analysis. Rather, our results indicate that choosing any
of the vaccine products would be highly cost-effective relative to
no vaccination [25].
This work examined how costs may vary across vaccine prod-
ucts, countries at different levels of Gavi support, payer, and cost
category. Rotarix resulted in the lowest-cost vaccination program
from both the country and country plus Gavi perspective (Fig. 1).
There is no single driver of this finding. However, it is clear that
the two-dose schedule for Rotarix plays an important role in
determining both vaccine and health systems costs. Interestingly,
lower wastage rates (e.g. 5%) for ROTAVAC had little impact on
our findings. While Rotarix was uniformly less costly and more
cost-effective across these countries (assuming equal effectiveness
across products), this finding is sensitive to relatively modest
changes in input values. Table 5 demonstrates that relatively small
decreases in the incremental health system cost per dose for one of
the new vaccines has the potential to tilt the economic benefits in
favor of a new vaccine. The small magnitude of changes necessary
and the general uncertainty around estimates of incremental
health system costs per dose suggest that the economic benefits
of alternative vaccines should be considered carefully, ideally
through a country-specific evaluation. This may not be feasible in
all cases, but this analysis suggests additional study would be valu-
able in some settings.
This analysis has several limitations. We do not have sufficient
information to differentiate vaccine effectiveness or waning across
products, and we assume all vaccine products have equivalent
effectiveness over time. Future studies may help clarify perfor-
mance differences. This analysis is therefore driven by cost differ-
ence: particularly, by the interplay of doses per course, per-dose
price, co-financing, and wastage rates. Critically, we do not have
precise estimates of incremental health systems cost per dose for
current products or yet know how this cost may vary by product.
Likewise, estimates of wastage are uncertain for newer products
and rates may fall over time as delivery is optimized. To address
these concerns, we conducted threshold analyses and indicated
the incremental health system cost thresholds necessary for the
new vaccines to meet the cost and cost-effectiveness results of
Rotarix. It will be critical to empirically examine the actual deliv-
ery costs associated with the new vaccines, especially given the
effects of relatively small changes in incremental health system
costs. Finally, this analysis does not examine all Gavi countries,
but a selection based on prior modelling studies representing the
three main transition phases of Gavi support. We believe these
results are informative, but because they only reflect a specified
time period, broader analyses would likely lead to new learnings.
As countries move closer to graduation and beyond, they may
potentially lose access to ‘‘tail” prices [26]. Given the higher prices
that non-Gavi countries currently pay for rotavirus vaccines, an
analysis using higher prices for Rotarix is likely to be more favor-
able to new vaccine products. As these cost-effectiveness and
impact studies are typically done for 10- or 20-year periods, it will
be important for countries to consider the longer-term implica-
tions of vaccine choices as well as anticipated changes in the cost
structure of countries’ immunization programs.
The analysis conducted here supports the continued use of
Rotarix in Gavi-eligible countries. Because each of the examined
vaccine products is projected to be highly cost-effective, countries
should consider the relative merits of all products.
This analysis does not seek to present a case for choosing one
vaccine product over another but rather demonstrates that all
examined rotavirus vaccines would have substantial health impact
and be highly cost-effective relative to no vaccination. It provides
health economic evidence that may help inform vaccine choice
alongside a number of other factors. Country-specific analyses
would be key to account for parameters driving results such as dif-
ferences in incremental health system costs linked to any product.
5. Conclusion
This analysis demonstrates that all of the examined rotavirus
vaccines would be highly cost-effective relative to no vaccination.
We found Rotarix to be the least costly and most cost-effective
product in the three countries analyzed, but the differences can
be small and subject to change with minor adjustments to uncer-
tain input variables. A similar analysis examining non-Gavi coun-
tries paying higher vaccine prices would likely highlight
additional economic benefits of the new vaccines.
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Table 5
Incremental health system cost values, percentage and absolute decrease, at which cost and cost-effectiveness are equivalent across products.
Bangladesh Ghana Malawi
Incremental health system cost values
Rotarix (comparator) $0.54 $1.30 $0.42
ROTAVAC w/Gavi subsidy $0.38 $0.94 $0.24
ROTAVAC w/o Gavi subsidy $0.46 $0.97 $0.36
ROTASIIL w/Gavi subsidy $0.26 $0.42 $0.28
ROTASIIL w/o Gavi subsidy < 0 $0.16 < 0
Percentage and absolute decrease to achieve cost parity
ROTAVAC w/Gavi subsidy 30% ($0.16) 28% ($0.36) 43% ($0.18)
ROTAVAC w/o Gavi subsidy 15% ($0.08) 25% ($0.33) 14% ($0.06)
ROTASIIL w/Gavi subsidy 52% ($0.28) 68% ($0.88) 33% ($0.14)
ROTASIIL w/o Gavi subsidy N/A 88% ($1.14) N/A
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